Hepatocyte growth factor is upregulated in ischemic retina and contributes to retinal vascular leakage and neovascularization

Valeria E. Lorenc | Raquel Lima e Silva | Sean F. Hackett | Seth D. Fortmann | Yuanyuan Liu | Peter A. Campochiaro

Departments of Ophthalmology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Correspondence
Peter A. Campochiaro, The Wilmer Eye Institute, 815 Maumenee, The Johns Hopkins School of Medicine, 600 N. Wolfe Street, Baltimore, MD 21287-9277, USA.
Email: pcampo@jhmi.edu

Present address
Yuanyuan Liu, Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China

Funding information
Supported by National Eye Institute (NEI) Grant R01EB016121 and Wilmer Eye Institute Imaging Core Grant EY001765.

Abstract
In patients with macular edema due to ischemic retinopathy, aqueous levels of hepatocyte growth factor (HGF) correlate with edema severity. We tested whether HGF expression and activity in mice with oxygen-induced ischemic retinopathy supports a role in macular edema. In ischemic retina, HGF was increased in endogenous cells and macrophages associated with retinal neovascularization (NV). HGF activator was increased in and around retinal vessels potentially providing vascular targeting. One day after intravitreous injection of HGF, VE-cadherin was reduced and albumin levels in retina and vitreous were significantly increased indicating vascular leakage. Injection of VEGF caused higher levels of vitreous albumin than HGF, and co-injection of both growth factors caused significantly higher levels than either alone. HGF increased the number of macrophages on the retinal surface, which was blocked by anti-c-Met and abrogated in chemokine (C-C motif) ligand 2 (CCL2)−/− mice. Injection of anti-c-Met significantly decreased leakage within 24 hours and after 5 days it reduced retinal NV in mice with ischemic retinopathy, but had no effect on choroidal NV. These data indicate that HGF is a pro-permeability, pro-inflammatory, and pro-angiogenic factor and along with its activator is increased in ischemic retina providing support for a potential role of HGF in macular edema in ischemic retinopathies.

KEYWORDS
diabetic macular edema, hepatocyte growth factor activator, retinal vein occlusion, vascular leakage

1 | INTRODUCTION

Ischemic retinopathies are diseases in which damage to retinal blood vessels results in areas of poorly perfused retina causing stabilization of hypoxia-inducible factor-1 (HIF-1) which stimulates expression of multiple hypoxia-regulated genes.1,2 The two most common ischemic retinopathies are diabetic retinopathy and retinal vein occlusion (RVO) and in both the most common cause of vision loss is macular edema. Both diabetic macular edema (DME) and macular edema due to

Abbreviations: AMD, age related macular degeneration; C57BL/6, C57 Black; CCL2, chemokine (C-C motif) ligand 2; c-MET, tyrosine-protein kinase Met; DME, diabetic macular edema; GFAP, glial fibrillary acidic protein; HGF, hepatocyte growth factor; NV, neovascularization; OIR, oxygen-induced ischemic retinopathy; RVO, retinal vein occlusion.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors.
RVO are substantially benefitted by suppression of VEGF, but some patients with these disease processes have residual edema despite frequent anti-VEGF injections. Intraocular steroids, such as the dexamethasone implant (Ozurdex®), are a second-line treatment for patients with DME or RVO who respond sub-optimally to VEGF suppression and are felt to work by reducing the production of other undetermined pro-permeability factors. In the Ozurdex for Retinal Vein Occlusion (ORVO) study, patients with macular edema poorly responsive to VEGF suppression had aqueous samples taken before and after intravitreal injection of a dexamethasone implant. Most of these patients showed substantially greater edema reduction after injection of a dexamethasone implant than after injection of a specific inhibitor of VEGF. In many such patients, protein arrays demonstrated that hepatocyte growth factor (HGF) was high at baseline, decreased as edema decreased and increased as edema returned. A similar experimental design was used in patients with DME poorly responsive to VEGF suppression in the Diabetic Macular Edema treated with Ozurdex (DMEO) trial and once again several patients had high aqueous levels of HGF at baseline that decreased as edema improved and increased as edema worsened.

Hepatocyte growth factor is best known for its effects in cancer. It was isolated from platelets and found to stimulate hepatocyte growth. Subsequently it was found to be identical to scatter factor, a fibroblast-derived stimulator of epithelial cell motility. The receptor for HGF, tyrosine-protein kinase Met (c-Met), was first isolated from a human osteosarcoma cell line in which there was a DNA rearrangement fusing the translocated promoter region to the MET gene resulting in high expression of c-Met. Many tumors, particularly melanomas, have mutations in MET that result in high expression or constitutive stimulation, and high levels of c-Met and/or HGF are associated with poor prognosis in many types of cancer. The activities of HGF/c-Met signaling most linked to tumor progression are mitogenesis, migration, invasive growth, and metastasis; however, stimulation of angiogenesis has also been implicated. HGF and c-Met are increased in hypoxic tissue and in adult mice immediately after rupture of Bruch’s membrane. A pulled glass micropipette was used to penetrate the sclera 1 mm posterior to the limbus and a foot switch activated a pump to inject 1 μL containing 3 mmol/L anti-c-Met (R&D Systems) or 6.25 mmol/L recombinant human HGF (Peprotech) in one eye, and 3 mmol/L mouse IgG (Equitech-Bio, Kerrville, TX, USA) or 7.5 mmol/L albumin (Sigma-Aldrich) in the fellow eye.

Mice with OIR were euthanized at P17, eyes were fixed in 10% phosphate-buffered formalin for 4 hours at 22°C, retinas were dissected out intact, stained with Alexa Fluor 488-conjugated Griffonia simulcipolia agglutinin (GSA) lectin (1:250; Invitrogen) for 45 minutes, flat mounted and examined by fluorescence microscopy. Photographs were obtained at 5× magnification and merged into a single image to show the entire retina using Photoshop CS5.1. An observer masked with regard to treatment group measured the area of NV per retina by image analysis using image analysis with Image-Pro Plus software (Media Cybernetics).

Mice with rupture of Bruch’s membrane were euthanized 7 days after laser, eyes were fixed in 10% phosphate-buffered formalin for 4 hours at 22°C, retinas were removed and eye cups containing retinal pigmented epithelium, choroid, and sclera were stained with GSA lectin and flat mounted. Flat

## 2. MATERIALS AND METHODS

### 2.1 Mouse model of OIR

Mice were treated in accordance with the Association for Research in Vision and Ophthalmology Guidelines on the care and use of animals in research. Oxygen-induced ischemic retinopathy (OIR) was produced by placing litters of C57BL/6 mice in 75 ± 3% oxygen at P7 and returning them to room air at P12. The retina immediately becomes hypoxic upon return to room air as demonstrated by upregulation of HIF-1α within 6 hours and remains hypoxic beyond P17, the peak of neovascularization (NV). Mice with OIR were euthanized at P13, P15, or P17 for studies described below.

### 2.2 Mouse model of choroidal NV due to laser-induce rupture of Bruch’s membrane

Laser photocoagulation-induced rupture of Bruch’s membrane was used to generate choroidal NV as previously described. Briefly, 4- to 5-week-old C57BL/6 mice were anesthetized, pupils were dilated with 1% tropicamide (Alcon Labs, Inc), and Bruch’s membrane was ruptured at 9, 12, and 3 o’clock positions of the posterior pole with 532 nm diode laser photocoagulation (75 μm spot size, 0.1 s duration, 140 mW) using the slit lamp delivery system of an OcuLight GL Photocoagulator (Iridex, Mountain View) and a handheld cover slide as a contact lens.

### 2.3 Effect of HGF or anti-c-Met on retinal and choroidal NV

Intravitreal injections were done in mice with OIR at P12 and in adult mice immediately after rupture of Bruch’s membrane. A pulled glass micropipette was used to penetrate the sclera 1 mm posterior to the limbus and a foot switch activated a pump to inject 1 μL containing 3 mmol/L anti-c-Met (R&D Systems) or 6.25 mmol/L recombinant human HGF (Peprotech) in one eye, and 3 mmol/L mouse IgG (Equitech-Bio, Kerrville, TX, USA) or 7.5 mmol/L albumin (Sigma-Aldrich) in the fellow eye.

Mice with OIR were euthanized at P17, eyes were fixed in 10% phosphate-buffered formalin for 4 hours at 22°C, retinas were dissected out intact, stained with Alexa Fluor 488-conjugated Griffonia simulcipolia agglutinin (GSA) lectin (1:250; Invitrogen) for 45 minutes, flat mounted and examined by fluorescence microscopy. Photographs were obtained at 5× magnification and merged into a single image to show the entire retina using Photoshop CS5.1. An observer masked with regard to treatment group measured the area of NV per retina by image analysis using image analysis with Image-Pro Plus software (Media Cybernetics).

Mice with rupture of Bruch’s membrane were euthanized 7 days after laser, eyes were fixed in 10% phosphate-buffered formalin for 4 hours at 22°C, retinas were removed and eye cups containing retinal pigmented epithelium, choroid, and sclera were stained with GSA lectin and flat mounted. Flat
mounts were examined by fluorescence microscopy and the area of choroidal NV at each Bruch’s membrane rupture site was measured by a masked investigator and the three measurements in each eye were averaged to provide a single experimental value.

### 2.4 Immunostaining of ocular sections from mice with OIR

Mice with OIR or controls were euthanized at P15 or P17 and eyes were frozen in optimum cutting temperature compound (Sakura-Finetek) and stored at −80°C. Ten µm sections were fixed in 4% paraformaldehyde (PFA) for 5 minutes at 22°C, washed with PBS and blocked 45 minutes in PBST containing 10% chicken serum (Sigma-Aldrich). Sections were incubated overnight at 4°C with goat anti-mouse HGF antibody (1:80; R&D Systems), goat anti-mouse HGF activator (HGFA) antibody (1:50; R&D Systems), or rabbit anti-glial fibrillary acidic protein (GFAP) (1:100; Dako). The anti-mouse HGFA antibody predominantly binds the inactive precursor of HGFA, pro-HGFA, and binds HGFA will lower affinity. Sections were washed and incubated in Alexa Fluor 647- or 594-conjugated GSA, Alexa Fluor 594-conjugated chicken anti-rabbit (1:650), Alexa Fluor 488-conjugated chicken anti-goat (1:650) or Alexa Fluor 594-conjugated chicken anti-goat (1:650) for 1 hour at 22°C; and then incubated for 5 minutes in Hoescht (1/3000; Sigma-Aldrich).

### 2.5 Immunostaining of retinal flat mounts

Mice with OIR or controls were euthanized at P17 and eyes were fixed with 4% PFA for 1 hour at 22°C. Retinas were dissected intact and blocked and permeabilized in phosphate-buffered saline (PBS) containing 10% horse serum (Sigma-Aldrich) and 0.3% Triton-X-100 (PBST) for 1 hour at 22°C. Then the tissues were incubated in anti-mouse HGF antibody (1:100; R&D Systems) and brilliant violet 421-conjugated anti-mouse F4/80 (1:100; Biolegend) overnight at 4°C in PBST. Retinas were washed with PBST and incubated with Alexa Fluor 594- or 488-conjugated GSA lectin (1:250; Invitrogen), and anti-mouse F4/80 Brilliant blue 421-conjugated primary (1:150; Biolegend) overnight at 4°C. The retinas were washed with PBS and examined using a confocal laser-scanning microscope (Zeiss LSM 710; Carl Zeiss, Inc.). For the quantification of F4/80 positive cells, complete retinal whole mount images were analyzed and the total number of positive F4/80 cells in each retina was quantified using ImageJ software (National Institutes of Health).

### 2.6 Quantitative real-time PCR

Mice with OIR or controls were euthanized at P13, P15, or P17, retinas were dissected and homogenized in 200 µL Trizol. To test the effect of overexpression of VEGF on expression of HGF, P21, and P30 rho/VEGF transgenic mice in which the rhodopsin promoter drives high expression of VEGF in the retina were euthanized and retinas were dissected and homogenized in 200 µL Trizol. In other experiments, adult C57BL/6 mice were anesthetized and given an intraocular injection of 1 µL of 6.25 mmol/L HGF or 6.25 mmol/L VEGF (R&D Systems) in one eye and PBS in the fellow eye. Mice were euthanized at 1 or 3 days after injection and retinas were removed and homogenized in Trizol. Total RNA was extracted with Direct-zol™ RNA kits (Zymo Research) in which centrifuge columns were pre-treated with DNAase to remove contaminating genomic DNA. Total RNA was suspended in RNAase free water and placed in RNAase-free tubes. The concentration of extracted RNA was measured with the NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific), normalized to the lowest concentration, reverse transcribed with Superscript III (Invitrogen). All cDNA samples were aliquoted and stored at −80°C. PCR primers targetting mouse HGF (F: TGAACCTGCAATGGTGAAAGC, R: GGGTCAAGAGTGTAGCACCA), VEGF (F: CAGCGGA GACAATGGGATGA, R: CTGGAAGTGAGCACAATGTGC), mouse CCL2 (F: TTAAAACCTGGATCGGAACCAA, R: GCATTAGCTTCAGATTACGGGT), and cyclophilin A as housekeeping gene, were used. Standard curves were made for each product before quantification. Real-time quantitative PCR was performed using a Rotor-Gene Q instrument and Rotor-Gene SYBR Green PCR Kit (Qiagen). The mRNA for each target gene was normalized to 10⁶ copies of cyclophilin A. A standard curve was made for each molecule before quantification and fold changes in genes expression were calculated using ΔΔCt values.

### 2.7 Measurement of HGF effect on retinal vascular leakage

Adult C57BL/6 mice were anesthetized and had intraocular injection of 1 µL of 6.25 µmol/L HGF or VEGF₁₆₅ (R&D Systems) in one eye and PBS in the fellow eye. At 1 and 3 days after injection, some of the mice were anesthetized and chests were opened to expose the heart; a 27-gauge cannula was inserted into left ventricle, the right atrium was cut for drainage, and the vasculature was flushed with PBS for 3 minutes, and retinas were dissected intact. Retinas or vitreous samples were sonication in PBS/0.3% Triton buffer containing phosphatase and protease inhibitors (Roche), centrifugation at 9200 g for 10 minutes, and supernatants were stored at −20°C. Albumin levels in retinal or vitreous samples were
measured using the albumin ELISA kit (ab108791, Abcam). The protein concentrations of retinal lysates were measured by the BioRad protein assay and 2 μg of total protein was added to each well. One μL of each vitreous sample was added to each well. Plates were read at 450 and at 570 nm and albumin levels were determined by plotting values on a standard curve.

2.8 | Effect of anti-c-Met on vascular leakage in mice with OIR

At P17, mice with OIR were given an intraocular injection of 1 μL of 3 mmol/L anti-c-Met in one eye and 1 μL of 3 mmol/L mouse IgG in the fellow eye. After 24 hours, mice were euthanized, vitreous samples were collected and vitreous albumin levels were measured as described above.

2.9 | Measurement of retinal leukostasis

Adult C57BL/6 mice were given an intravitreal injection of 1 μL of 6.25 mmol/L HGF or 6.25 mmol/L VEGF in one eye and 1 μL of PBS in the fellow eye. Twenty-four hours after injection, leukostasis was measured as previously described.\(^1\) Briefly, mice were anesthetized, the chest was opened to expose the heart, the right atrium was cut for drainage, a 27-gauge cannula was inserted into left ventricle, and the vasculature was flushed with PBS for 3 minutes to removal all nonadherent cells. Mice were then perfused over a span of 2-3 minutes with rhodamine- or FITC-labeled conA (20 μg/mL in PBS, 5 mg/kg; RL-1002 and FL-1001; Vector Labs Thermofisher). The vasculature was flushed for 4 minutes with PBS to remove residual unbound con A. In some experiments, the vasculature was also perfused with fluorescein-labeled dextran (Sigma-Aldrich). Eyes were removed and fixed in 2% PFA for 2 hours at room temperature and retinas were dissected and flat mounted. Retinas were examined by fluorescence microscopy and the number of intravascular leukocytes throughout the entire retina were counted by an investigator masked with respect to treatment group.

2.10 | Immunoblots

Fifty μg of retinal lysates were added to Bolt LDS Sample Buffer (Thermo Fisher Scientific), resolved by 4%-12% gradient SDS-PAGE and transferred to PDVF membranes for immunoblot analysis. Membranes were probed with primary antibodies against mouse VE-Cadherin (1:2500; R&D Systems); mouse HGF (1:5000; R&D Systems) and actin (1:2000; Cell Signaling). Secondary antibodies were donkey anti-rabbit (1:10 000, GE Healthcare) and rabbit anti-goat (1:20 000, Thermo Fisher Scientific).

2.11 | Statistics

In experiments in which an experimental group was compared to its own control group, statistical comparisons were made by unpaired Student's \( t \) test. In experiments in which multiple experimental groups were compared, comparisons were made by 2 way-ANOVA with using Newman-Keuls Multiple Comparison Test or one way-ANOVA with Bonferroni’s correction for multiple comparisons.

3 | RESULTS

3.1 | HGF is increased in ischemic retina

There was faint immunofluorescent staining for HGF in the retinas of room air-raised P15 mice (Figure 1A, left column) that could be related to retinal vascular development, because it was less in the retinas of P17 mice raised in room air (Figure 1A, third column). The retinas of mice with OIR mimic aspects of the retinas of patients with ischemic retinopathies including retinopathy of prematurity, proliferative diabetic retinopathy, and RVO. Staining for HGF was increased in ischemic retina of mice with OIR at P15 and P17 (Figure 1A, top row). The difference in HGF staining between non-ischemic and ischemic retina at P17 is best seen in the magnified view in Figure 1B, top row. Visualization of retinal vascular endothelial cells by staining with GSA lectin shows normal superficial, intermediate, and deep capillaries in the retinas of P15 and P17 retinas from room air-raised mice and retinal NV on the surface of the retina of OIR mice that was mild at P15 and severe at P17 (Figure 1A,B, second row). Some of the HGF staining co-localized with staining for GFAP, indicating that it was present in astrocytes on the surface of the retina and Muller cells throughout the inner retina, but there were also many HGF-stained cells that were not GFAP-positive, indicating that other cells in the inner retina also expressed HGF (Figure 1A,B, third row). Quantitative real time PCR confirmed a significant increase in expression of \( hgff \) mRNA in retinas of P15 and P17 OIR mice compared with RA-reared mice (Figure 1C).

Immunofluorescent staining of retinal flat mounts from P17 room air-reared mice showed HGF-positive (Figure 2A), F4/80-positive (Figure 2B) macrophages on the surface of the retina with some in close association with superficial retinal vessels (Figure 2C, arrowheads). Retinal flat mounts from P17 mice with OIR showed an increase in HGF-positive (Figure 2D), F4/80-positive (Figure 2E)
FIGURE 1  HGF is increased in ischemic retina. At P15 and P17, mice with oxygen-induced ischemic retinopathy and control mice raised in room air were euthanized and 10 µm ocular frozen sections were immunostained for HGF (green) and GFAP (red), histochemically stained with GSA lectin (white) which stains vascular cells, and Hoechst (blue) to stain nuclei (A). The retinal layers, GCL, IPL, INL, outer plexiform layer, and ONL, are labeled in the panels of the bottom row (scale bar = 50 µm). A magnified view of the regions within the rectangles are shown in (B) (scale bar = 25 µm). Retinas were dissected from P13, P15, and P17 mice with OIR and RA controls (n = 8 for each time point) and quantitative real time PCR was used to measure the number of HGF transcripts per 10^6 cyclophillin A transcripts (C). Bars represent mean (± SEM). **P < .05, *P < .01 for difference from control by unpaired t test. GCL, ganglion cell layer; GFAP, glial fibrillary acidic protein; HGF, hepatocyte growth factor; INL, inner nuclear layer; IPL, inner plexiform layer; OIR, oxygen-induced ischemic retinopathy; ONL, outer nuclear layer; RA, room air.

FIGURE 2  Ischemic retina contains increased HGF-positive macrophages in close proximity to NV. At P17, mice with OIR or RA controls were euthanized and retinas were dissected intact, stained with anti-HGF (red) and F4/80 (blue), flat mounted, and examined by confocal microscopy. Retinas of RA control mice had sparse HGF-positive (A), F4/80-positive (B) macrophages on the surface of the retina in close association with GSA (green) lectin-stained blood vessels (C). Retinas of OIR mice showed increased numbers of HGF-positive macrophages (D, E) on the surface of the retina in close proximity to NV (F). Scale bar = 50 µm. GSA, Griffonia simplicifolia agglutinin; HGF, hepatocyte growth factor; NV, neovascularization; OIR, oxygen-induced ischemic retinopathy; RA, room air.
Hepatocyte growth factor is synthesized in an inactive pro-form (pro-HGF) and cleavage by a serine protease is required to convert pro-HGF to active, mature HGF. A particularly important protease is HGFA, which is proteolytically cleaved to HGFA. Immunoblots from an enzymatically inactive precursor, pro-HGFA, which is derived from an enzymatically inactive precursor, pro-HGFA, showed staining for pro-HGFA in retinas from mice with OIR compared with those from eyes injected with PBS (Figure 3A). Densitometry showed a significant increase in the pro-HGFA/actin ratio at P13 and P15 in retinas from mice with OIR vs those from control mice (Figure 3B). There was no detectable immunofluorescent staining for pro-HGFA in the retinas of P15 control mice at low (Figure 3C) or high magnification (Figure 3D), but there were many lightly stained cells primarily in the inner retina of P15 OIR mice (Figure 3E) best seen with high magnification (Figure 3F). Compared with GSA lectin-stained retinal vessels in P15 control mice (Figure 3G,H), vessels in P15 mice with OIR were dilated and showed staining for pro-HGFA (Figure 3J). While staining was strongest in vascular cells, there was also staining for pro-HGFA in non-vascular cells around vessels. Staining of nuclei with Hoesch allowed identification of all of the retinal layers (Figure 3K-N) and much of the non-vascular staining for pro-HGFA in retinas from mice with OIR was in the inner plexiform layer (Figure 3M,N). The predominantly vascular localization is interesting and may provide a means of targeting active HGF to endothelial cells.

3.2 The precursor of HGFA is increased in ischemic retina

HGF causes retinal vascular leakage

One or 3 days after intravitreous injection of 1 μL of 6.25 mmol/L HGF or 6.25 mmol/L VEGF in one eye and PBS in the fellow eye, C57BL/6 mice were perfused through the left ventricle with PBS to remove intravascular proteins and the concentration of albumin in retinal homogenates was measured by ELISA. At 1 day after injection, the mean retinal concentration of albumin was significantly increased in eyes injected with HGF compared with fellow eyes injected with PBS (Figure 4A). Extravascular albumin diffuses into the avascular vitreous and albumin measurements in vitreous samples eliminate the need for perfusion to remove all extravascular albumin. The experiment was repeated and albumin was measured in vitreous samples. One day after intravitreous injection of 1 μL of 6.25 mmol/L HGF, mean albumin concentration in the vitreous was significantly higher than that in PBS-injected fellow eyes, but not as high as that in eyes injected with an equimolar amount of VEGF (Figure 4B). The VEGF-induced leakage was transient and the excess albumin was cleared from the vitreous within days, because at 3 days after injection, mean albumin level in VEGF-injected eyes was similar to that in fellow eye controls; however, there was still significant elevation above controls in HGF-injected eyes suggesting more prolonged barrier disruption. Co-injection of VEGF and HGF resulted in a significantly higher mean vitreous albumin concentration than either alone (Figure 4C), suggesting additive effects on vascular leakage. One day after intravitreous injection of 1 μL of 6.25 mmol/L HGF or PBS, immunoblots of retinal homogenates showed a significant reduction in VE-cadherin in retinas from HGF-injected eyes compared with those from eyes injected with PBS (Figure 4D). Compared with retinas from eyes injected with PBS, those from eyes injected with 1 μL of 6.25 mmol/L HGF showed no difference in mean vegf mRNA level at 1 day (P = .16) or 3 days (P = .90) after injection (Figure 4E). Conversely, retinas from eyes injected with 1 μL of 6.25 mmol/L VEGF had no difference in mean level of hgf mRNA compared with retinas from eyes injected with PBS at 1 (P = .46) or 3 days (P = .28) after injection (Figure 4F). Similar to an injection of VEGF, sustained expression of VEGF did not increase expression of HGF in the retina, because at P21 and P30, mean retinal level of hgf mRNA was not significantly different in rho/ VEGF transgenic mice with increased expression of VEGF in the retina compared with age-matched wild-type mice (Figure 4F, P = .66 at P21 and P = .24 at P30). Therefore high levels of HGF do not increase expression of VEGF in the retina, and high levels of VEGF do not increase expression of HGF.

3.4 HGF increases extravascular macrophages in the retina, but does not cause leukocytic plugging in retinal vessels

One day after intravitreous injection of 1 μL of 6.25 mmol/L HGF, the density of F4/80-positive macrophages on the retinal surface was dramatically greater than that seen after injection of PBS (Figure 5A, top two rows and Figure 5B). Compared with eyes injected with HGF, those injected with anti-c-Met prior to injection of HGF showed a striking reduction in macrophages on the retinal surface (Figure 5A, row 3 and Figure 5B), indicating that stimulation of c-Met on macrophages was necessary for their recruitment. Interestingly, chemokine (C-C motif) ligand 2 (CCL2)−/− mice also failed to show HGF-induced macrophage recruitment into the...
indicating that prior activation of macrophages with CCL2 was necessary for macrophage responsiveness to HGF (Figure 5A bottom row and Figure 5B). In wild-type mice, retinal mRNA for CCL2 was significantly increased after intraocular injection of HGF (Figure 5C).

We have previously demonstrated that increased intraocular levels of VEGF increase intravascular adherent leukocytes in the retina causing leukocytic plugging of retinal vessels, however extravascular F4/80-positive macrophages were not increased by intraocular injection of 1 µL of 6.25 mmol/L VEGF (Figure 5B). Conversely, intravascular leukocytes were not increased by intraocular injection of 1 µL of 6.25 mmol/L HGF (Figure 6A,B). However, high magnification views of retinal flat mounts from eyes injected with HGF showed macrophages adherent to the outer wall of retinal vessels and GSA lectin as well as F4/80 as previously described and were closely associated with retinal vessels (Figure 6C).

3.5 | HGF contributes to ischemia-induced retinal NV and retinal vascular leakage

At P12 in mice with OIR, the onset of the ischemic period, eyes were given an intravitreous injection of 1 µL containing HGFA is increased in ischemic retina primarily in and around retinal blood vessels. At P13, P15, and P17, mice with OIR or RA controls were euthanized and immunoblots showed increased levels of HGFA in retinal homogenates of OIR mice compared with RA mice at P13 and P15 (A and B). Bars show the mean (± SEM) HGFA/Actin ratio of densitometry readings for blots from five mice in each group (P < .05 for difference from corresponding RA control by unpaired t test). Frozen ocular sections from P15 RA controls and OIR mice were immunostained for HGFA (green, C-N), histochemically stained with GSA lectin to stain vascular cells (red, G-N), and nuclei were stained with Hoechst (blue, K-N). Low magnification images (C, E, G, I, K, M; scale bar = 50 μm) and high magnification images of the region within the rectangle in K (D, H, L; scale bar = 15 μm) and M (F, J, N; scale bar = 15 μm) are shown. There was no detectable staining for HGF in retinas from RA control mice at low (C, G, K) or high magnification (D, H, L), but clearly identifiable staining in the retinas of OIR mice (E, F), primarily in and around retinal vessels (I, J). The retinal layers, GCL, IPL, INL, outer plexiform layer, and ONL, are labeled in the panels with nuclear stain (K-N). GCL, ganglion cell layer; GSA, *Griffonia simplicifolia* agglutinin; HGF, hepatocyte growth factor; HGFA, HGF activator; INL, inner nuclear layer; IPL, inner plexiform layer; OIR, oxygen-induced ischemic retinopathy; ONL, outer nuclear layer; RA, room air.
6.25 mmol/L HGF, 7.5 mmol/L albumin, 3 mmol/L anti-c-Met antibody, or 3 mmol/L control IgG. At P17, the area of retinal NV per retina was measured on retinal flat mounts. Compared with eyes injected with albumin, those injected with HGF had a significant increase in the mean area of retinal NV (Figure 7A, top row), and compared with those injected with control IgG, those injected with anti-c-Met had a significant reduction in mean area of retinal NV (Figure 7B). This suggests that HGF contributes to ischemia-induced retinal NV.

To test the effect of HGF on vascular leakage in mice with OIR, it is necessary to use a brief treatment period that is too short to have an effect on NV. At P17 mice with OIR were given an intraocular injection of 1 µL containing 6.25 mmol/L HGF, 7.5 mmol/L albumin, 3 mmol/L anti-c-Met antibody, or 3 mmol/L control IgG and after 7 days the area of choroidal NV at Bruch’s membrane rupture sites was significantly less in mice treated with anti-c-Met (Figure 7C).

### 3.6 Exogenous HGF stimulates choroidal NV at Bruch’s membrane rupture sites, but endogenous HGF is not a major contributor

Laser-induced rupture of Bruch’s membrane in mice is a widely used model that predicted the importance of VEGF in neovascular age-related macular degeneration.29,38,39 Immediately after rupture of Bruch’s membrane, eyes were given an intravitreous injection of 1 µL containing 6.25 mmol/L HGF, 7.5 mmol/L albumin, 3 mmol/L anti-c-Met, or 3 mmol/L control IgG and after 7 days the area of choroidal NV at Bruch’s membrane rupture sites was
HGF reduces VE-cadherin and causes retinal vascular leakage. Adult C57BL/6 mice were given an intravitreous injection of 1 μL of 6.25 mmol/L HGF or 6.25 mmol/L VEGF in one eye and 1 μL of PBS in the fellow eye. At 1 or 3 days after injection, the mice were perfused through the left ventricle with PBS and retinas were removed. (A), or vitreous samples were obtained. (B). Retinal lysates had measurement of protein levels and measurement of albumin by ELISA. The bars show the mean (± SEM) albumin level per μg protein with n shown within bars. (A). In (B), the bars show the mean (± SEM) albumin level per μL of vitreous measured by ELISA. (C) In an independent experiment, mice were given an intravitreous injection in one eye of 1 μL of 6.25 mmol/L HGF, 6.25 mmol/L VEGF, or 6.25 mmol/L of each. Vitreous samples were obtained 1 day after injection and vitreous albumin levels were measured by ELISA. The bars show the mean (± SEM) albumin level per μL of vitreous. (D) One day after injection of 1 μL of 6.25 mmol/L HGF in one eye and PBS in the fellow eye, retinal lysates were immunoblotted for VE-Cadherin and actin. Bars represent the mean (± SEM) VE-Cadherin/Actin ratio of densitometry readings for blots from five mice in each group. (E) One or 3 days after intravitreous injection of 1 μL of 6.25 mmol/L HGF in one eye and PBS in the fellow eye, retinas were isolated and quantitative real time PCR was done to measure mRNA for VEGF and cyclophilin. Bars represent the mean (± SEM) veg transcripts per 10^6 cyclophilin transcripts and there was no significant difference between retinas from HGF-injected and PBS-injected eyes. (F) One or 3 days after intravitreous injection of 1 μL of 6.25 mmol/L VEGF in one eye and PBS in the fellow eye, retinas were isolated and quantitative real time PCR was done to measure mRNA for HGF and cyclophilin. Bars represent the mean (± SEM) hgf transcripts per 10^6 cyclophilin transcripts and there was no significant difference between retinas from VEGF-injected and PBS-injected eyes. At P21 and P30, transgenic mice in which the rhodopsin promoter drives expression of VEGF in the retina (rho/VEGF mice) and control wild-type mice were euthanized, retinas were isolated, and quantitative real time PCR was done to measure mRNA for HGF and cyclophilin. Bars represent the mean (± SEM) hgf transcripts per 10^6 cyclophilin transcripts in the retina and there was no significant difference between retinas from rho/VEGF and wild-type (C57) mice at P21 or P30. *P < .05, **P < .01, and +++P < .001 for difference from control by ANOVA with correction for multiple comparisons using Newman-Keuls Multiple Comparison Test (A-C) or by unpaired t test (D-E). HGF, hepatocyte growth factor.

measured. Compared with eyes injected with albumin, the mean area of choroidal NV was significantly greater in eyes injected with HGF (Figure 7D), indicating that HGF stimulates the growth of choroidal NV. However, compared with eyes injected with control IgG, the mean area of choroidal NV was not significantly less in eyes injected with anti-c-Met (Figure 7E), suggesting that endogenous HGF is not a major contributor in this model.

4 | DISCUSSION

Recent clinical trials have implicated HGF as a potential contributor to macular edema in patients with DME or RVO in whom suppression of VEGF has a suboptimal response. The primary purpose of this study was to determine if the expression and activity of HGF in mouse models provide support for such a role for HGF. In mice with ischemic retinopathy, expression of HGF was increased in both glial and neuronal cells throughout the inner retina and in mononuclear cells that closely associated with NV on the surface of the retina. Compared with normal control mice, the retinal level of hgf mRNA was increased in mice with OIR confirming the findings of Columbo et al. It is also consistent with studies that have measured increased levels of HGF in the vitreous of patients with proliferative diabetic retinopathy or central RVO compared with controls. However, increased levels of immunoreactive HGF or mRNA for HGF is not necessarily indicative of increased HGF activity, because an inactive form of HGF, pro-HGF is secreted from hypoxic cells, and must be cleaved by serine proteases to form active HGF. The primary serine protease responsible for this is HGFA, which is also derived from a larger inactive protein, pro-HGFA. There was no detectable pro-HGFA in normal retina, but it was present in ischemic retina, predominantly in and around vascular cells, which could serve to target active HGF to endothelial cells. Homing of HGF-positive macrophages to vessels (Figure 2) may play a similar role.

Previous studies focused on possible contribution of HGF to ischemia-induced retinal NV. Our data support this possibility because suppression of HGF signaling by blocking c-Met reduced retinal NV in mice with OIR confirming the findings of Columbo et al. However, we were particularly interested in whether HGF could contribute to macular edema in ischemic retinopathies, in which VEGF is important, but is not the only stimulator of retinal vascular leakage. Compared with injection of PBS, intravitreous injection of HGF caused greater vascular leakage as evidenced by elevated albumin in the retina or vitreous. We have recently demonstrated that albumin levels in the vitreous correlate well with assessment of vascular leakage severity by fluorescein angiography. Additional validation of the usefulness of this approach is provided in the current study because the relative changes in vitreous albumin levels after HGF injection mirrored the changes in retinal albumin levels of perfused mice in which all intravascular albumin was eliminated. These results are consistent with the observation that intravitreous injection of HGF in rats causes increased leakage measured by vitreous fluorophotometry. Compared with intravitreous injection of HGF, injection of an equimolar amount of VEGF caused more than twice as much leakage, but interestingly co-injection of HGF and VEGF caused significantly greater leakage than either alone. HGF has previously been shown to act synergistically with VEGF to enhance endothelial cell survival and tube formation in collagen gels, and corneal angiogenesis, and the current study indicates that VEGF and HGF also work cooperatively in promoting vascular leakage in...
the retina. There was severe leakage in mice with ischemic retinopathy that was significantly reduced by anti-c-Met indicating that HGF contributes to vascular leakage in ischemic retina.

Previous studies have shown that HGF stimulates angiogenesis in vitro\textsuperscript{19,20} and acts directly on confluent monolayers of vascular endothelial cells to reduce transendothelial resistance, increase permeability, and reduce levels of the tight junction protein occludin.\textsuperscript{21} We found that HGFA was undetectable in normal retina and was upregulated in retinal vessels of ischemic retina and that intraocular injection of HGF reduced levels of VE-cadherin, an endothelial-specific gene. Taken together, these findings suggest that HGF...
acts directly on retinal endothelial cells to disrupt junctional proteins and increase vascular permeability.

In addition to direct effects on the vasculature to increase permeability, the HGF signaling system may contribute indirectly through recruitment of macrophages which produce pro-permeability factors that augment the direct effects of HGF on endothelial cells. Interestingly, HGF-induced recruitment of macrophages was reduced in CCL2−/− mice suggesting that CCL2 may be involved. This is consistent with the observations that CCL2 is increased in ischemic retina in association with macrophage influx and that HGF increases production of CCL2 by fibroblast-like synovial cells and increases macrophage infiltration of joints. Intracoronary administration of Ad-HGF increased serum levels of CCL2 and the percentage of CD34(+) and CD117(+) endothelial cell progenitor cells, a proposed mechanism for HGF-induced benefit in myocardial infarction. However, the effects of HGF on CCL2 differ in different tissues, because in kidney it reduces CCL2 production and is anti-inflammatory. Our data demonstrate that HGF is pro-inflammatory in the retina, an effect mediated at least in part by CCL2. In the retinas of diabetic rats, there is upregulation of CCL2 associated with monocyte/macrophage infiltration and breakdown of the blood-retinal barrier. Thus, HGF may act directly and indirectly through CCL2 to promote retinal vascular leakage. In addition, the increase in HGFA in ischemic retina may contribute to macrophage recruitment, because HGFA cleaves inactive macrophage stimulating protein into its active form, which directly stimulates macrophage chemotaxis and sensitizes macrophages to other chemoattractants.

Age-related macular degeneration (AMD) is a prevalent cause of moderate and severe vision loss in elderly individuals. Some patients with AMD develop choroidal NV that grows under the retina and leaks fluid that collects under or within the retina causing distortion and reduction of vision. Studies in animal models of choroidal NV indicated that VEGF plays a critical role and were confirmed in clinical trials that demonstrated marked improvement in vision of patients with neovascular AMD treated with monthly injections of a VEGF antagonist. While VEGF antagonists are highly efficacious in most patients with neovascular AMD, some respond sub-optimally to monthly injections suggesting that factors other than VEGF may also contribute to choroidal NV growth and leakage in those...
FIGURE 7  Suppression of HGF signaling reduces ischemia-induced retinal NV, but does not reduce choroidal NV at Bruch’s membrane rupture sites. At postnatal day (P) 12, mice with oxygen-induced ischemic retinopathy were given an intravitreal injection of 1 µL of 6.25 mmol/L HGF in one eye (n = 15) and 1 µL of 7.5 mmol/L albumin in the fellow eye (n = 15), 1 µL of 3 mmol/L anti-c-Met in one eye (n = 15) and 1 µL of 3 mmol/L control IgG in the fellow eye (n = 14, one eye was damaged and could not be used). At P17, mice were euthanized and retinal flat mounts were stained with GSA and the area of retinal NV was measured by a masked investigator. Representative images and graphs in which bars represent the mean (± SEM) indicate a significant increase in the RNV area in HGF-injected vs albumin-injected eyes (A) and a significant reduction in eyes injected with anti-c-Met compared with those injected with control IgG (B). Bars represent mean (± SEM). *P < .05, **P < .01 for difference from control by unpaired t test. Scale bar = 500 µm. (C) At P17 mice with OIR (n = 8) were given and injection of 1 µL of 3 mmol/L anti-c-Met in one eye and 1 µL of 3 mmol/L control IgG in the fellow eye. After 24 hours, vitreous samples were obtained and the level of albumin was measured by ELISA. There was a significant reduction in vitreous albumin in anti-c-Met-injected eyes compared with IgG controls. Bars represent mean (± SEM). *P < .05 for difference from control by unpaired t test. C57 Black mice had laser-induced rupture of Bruch’s membrane at three locations in each eye followed by intravitreal injection of 1 µL of 6.25 mmol/L HGF in one eye (n = 10) and 1 µL of 7.5 mmol/L albumin in the fellow eye (n = 10), or 1 µL of 3 mmol/L anti-c-Met in one eye (n = 10) and 1 µL of 3 mmol/L control IgG in the fellow eye (n = 9, one eye was damaged and could not be used). After 7 days, mice were euthanized and choroidal flat mounts were stained with *Griffonia simplicifolia* lectin. The area of choroidal NV at Bruch’s membrane ruptured sites was measured by a masked investigator and the three values for each eye were averaged to provide a single experimental value. Representative images and graphs in which bars represent the mean (± SEM) indicate a significant increase in the size of CNV in HGF-injected vs albumin-injected control eyes (D) and no significant difference in eyes injected with anti-c-Met vs IgG controls (E). *P < .05 by unpaired t test for difference from control. Scale bar = 100 µm. GSA, *Griffonia simplicifolia* agglutinin; HGF, hepatocyte growth factor; NV, neovascularization
patients. Thus, just like ischemic retinopathies, neovascular AMD is primarily driven by VEGF, but other factors may contribute. However, unlike the situation in ischemic retinopathy, we were unable to demonstrate a possible role for HGF in choroidal NV, because while exogenous HGF is capable of stimulating growth of CNV at Bruch’s membrane rupture sites, blockade of HGF signaling failed to significantly reduce choroidal NV. This does not rule out a role for HGF because this model may not mimic all aspects of neovascular AMD, but regardless our data provide no support.

In summary, in the search for other factors that contribute to macular edema in patients with ischemic retinopathy who respond sub-optimally to suppression of VEGF, clinical trials have identified HGF as a suspect. The current study provides additional circumstantial evidence because HGF is increased in ischemic retina as is its activator which is increased predominantly in and around retinal vessels. Furthermore HGF promotes retinal vascular leakage in an additive fashion with VEGF and suppression of HGF signaling reduce vascular leakage in ischemic retinopathy. Thus, the hypothesis that HGF contributes to macular edema in ischemic retinopathies has been supported, but to definitively test it, clinical studies are needed using specific HGF antagonists in patients with DME and RVO.

CONFLICT OF INTEREST

PAC is a consultant to Aerpio Therapeutics, Alimera, Allegro, Allergan, Applied Genetic Technologies, AsclipiX, Astellas, Exonate, Genentech/Roche, Intrexon, Merck, Novartis, and Rxi. PAC receives research funding from Aerpio Therapeutics, Alimera, Aerpio Therapeutics, Allergan, AsclipiX, Clearside, Genentech/Roche, Genzyme, Graybug, Oxford BioMedica, Regeneron, Regenxbio, and Rxi. PAC has equity in Allegro and Graybug. All of these potential conflicts of interests are managed by JHU. None of the other authors have any potential conflicts.

AUTHOR CONTRIBUTIONS

V. E. Lorenc and P. A. Campochiaro designed research; V. E. Lorenc, R. Lima e Silva, S. F. Hackett, S. D. Fortmann, and Y. Liu performed research; V. E. Lorenc, R. Lima e Silva, and P. A. Campochiaro analyzed the data; V. E. Lorenc and P. A. Campochiaro wrote the manuscript; all authors edited and approved the manuscript.

REFERENCES

1. Ozaki H, Yu A, Della N, et al. Hypoxia inducible factor-1a is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci. 1999;40: 182-189.
2. Kelly BD, Hackett SF, Hirota K, et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res. 2003;93:1074-1081.
3. Nguyen QD, Shah SM, Heier JS, et al.; Group, R.-S. Primary end point (six months) results of the Ranibizumab for Edema of the macula in Diabetes (READ-2) Study. Ophthalmology. 2009;116:2175-2181.
4. Nguyen QD, Brown DM, Marcus DM, et al.; Group, R. a. R. Ranibizumab for diabetic macular edema. Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789-801.
5. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator. Mol Ther. 2008;16:791-799.
6. Campochiaro PA, Heier JS, Feiner L, et al.; Group, B. S. Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study. Ophthalmology. 2010;117:1102-1112.
7. Brown DM, Campochiaro PA, Singh RP, et al.; Group, C. S. Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion: 6-month results of the phase III CRUISE study. Ophthalmology. 2010;117:2124-1133.
8. Campochiaro PA, Hafiz G, Mir TA, et al. Pro-permeability factors after dexamethasone implant in retinal vein occlusion; the Ozurdex for retinal vein occlusion (ORVO) study. Am J Ophthalmol. 2015;160:313-321.
9. Campochiaro PA, Hafiz G, Mir TA, et al. Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with Ozurdex study. Am J Ophthalmol. 2016;168:13-23.
10. Nakamura T, Teramoto H, Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci USA. 1986;83:6489-6493.
11. Stoker M, Gherardi E, Perryman N, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987;327:239-242.
12. Naldini L, Weidner KM, Vigna E, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 1991;10:2867-2878.
13. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Proc Natl Acad Sci USA. 1991;88:802-804.
14. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68-73.
15. Curz J, Res-Filho JS, Silva P, Lopes JM. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous melanoma. Oncology. 2003;65:72-82.
16. De Oliveira AT, Matos D, Loquilo AF, et al. MET is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res. 2009;29:4807-4811.
17. Weidner KM, Behrens J, Vandescherkove J, Birchmeier W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol. 1990;111:2097-2108.
18. Widner KM, Sachs M, Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol. 1993;121:145-154.
19. Bussolini F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility. J Cell Biol. 1992;119:629-641.
20. Grant DS, Kleinman HK, Goldberg ID, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA. 1993;90:1937-1941.

21. Jiang WG, Martin TA, Matsumoto K, Nakamura T, Mansel RE. Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells. J Cell Physiol. 1999;181:319-329.

22. Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70:10090-10100.

23. Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev. 2013;39:793-801.

24. Scarpino S, Cancellario d’Alena F, Napoli A, Pasquini A, Marzullo A, Ruco LP. Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol. 2004;201:352-358.

25. Colombo ES, Menicucci G, McGuire PG, Das A. Hepatocyte growth factor/scatter factor promotes retinal angiogenesis through increased urokinase expression. Invest Ophthalmol Vis Sci. 2007;48:1793-1800.

26. Katsuna Y, Okano T, Noritake M, et al. Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders. Diabetes Care. 1998;21:1759-1763.

27. Canton A, Burgos R, Hernandez C, et al. Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy. Br J Ophthalmol. 2000;84:732-735.

28. Smith LEH, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.

29. Tobe T, Ortega S, Luna JD, et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol. 1998;153:1641-1646.

30. Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol. 1997;151:281-291.

31. Yuan JS, Wang D, Stewart CNJ. Statistical methods for efficiency adjusted real-time PCR quantification. Biotechnol J. 2008;3:112-123.

32. Liu Y, Shen J, Fortmann SD, Wang J, Vestweber D, Campochiaro PA. Reversible retinal vessel closure from VEGF-induced leukocyte plugging. JCI Insight. 2017;2:95530.

33. Naldini L, Tamagnone L, Vigna E, et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 1992;11:4825-4833.

34. Miyazawa K, Shimomura T, Kitamura A, Kondo J, Morimoto Y, Kitamura N. Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem. 1993;268:10024-10028.

35. Miyazawa K, Shimomura T, Kitamura N. Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. J Biol Chem. 1996;271:3615-3618.

36. Kitajima Y, Ide T, Ohtsuka T, Miyazaki K. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci. 2008;99:1341-1347.

37. Sorokin SP, Hoyt RFJ. Macrophage development: I. Rationale for using Griffonia simplicifolia isolectin B4 as a marker for the line. Anat Rec. 1992;232:520-526.

38. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is an important stimulator in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:3158-3164.

39. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP/R12 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195:241-248.

40. Ehlken C, Grundel B, Michels D, et al. Increased expression of angiogenic and inflammatory proteins in vitreous of patients with ischemic central retinal vein occlusion. PLoS ONE. 2015;10:e0126859.

41. Fortmann SD, Lorenc VE, Shen J, Hackett SF, Campochiaro PA. Mousetap, a novel technique to collect uncontaminated vitreous or aqueous and expand usefulness of mouse models. Sci Rep. 2018;8:6371.

42. Clermont AC, Cahill M, Salti H, et al. Hepatocyte growth factor induces retinal vascular permeability via MAP-kinase and PI-3 kinase without altering retinal hemodynamics. Invest Ophthalmol Vis Sci. 2006;47:2701-2708.

43. Xin X, Yang X, Ingle G, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol. 2001;153:1111-1120.

44. Davies MH, Eubanks JP, Powers MR. Microglia and macrophages are increased in response to ischemia-induced retinopathy in the mouse retina. Mol Vis. 2006;12:467-477.

45. Dankbar B, Neugebauer K, Wunrath C, et al. Hepatocyte growth factor induction of macrophage chemoattractant protein-1 and osteopetrotic-inducing factors in osteoarthritis. J Orthop Res. 2007;25:569-577.

46. Yang ZJ, Xu SL, Chen B, et al. Hepatocyte growth factor plays a critical role in the regulation of cytokine production and induction of endothelial progenitor cell mobilization: a pilot gene therapy study in patients with coronary heart disease. Clin Exp Pharmacol Physiol. 2009;36:790-796.

47. Giannopoulou M, Dai C, Tan X, Wen X, Micalopoulos GK, Liu Y. Hepatocyte growth factor exerts its anti-inflammatory action by disrupting nuclear factor-kappaB signaling. Am J Pathol. 2008;173:30-41.

48. Rangasamy S, McGuire PG, Nitta CF, Monkcaraj F, Oruganti SR, Das A. Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy. PLoS ONE. 2014;9:e108508.

49. Kawaguchi M, Orikawa H, Baba T, Fukushima T, Kataoka H. Hepatocyte growth factor activator is a serum activator of single-chain precursor macrophage-stimulating protein. FEBS J. 2009;276:3481-3490.

50. Skeel A, Leonard EJ. Action and target cell specificity of human macrophage-stimulating protein (MSP). J Immunol. 1994;152:4618-4623.

51. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Ten-year incidence and progression of age-related macular degeneration: the Beaver Dam Eye study. Ophthalmology. 2002;109:1767-1779.

52. Kryzstolik MG, Afshari MA, Adams P, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular...
endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.

53. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.

54. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.

How to cite this article: Lorenc VE, Lima e Silva R, Hackett SF, Fortmann SD, Liu Y, Campochiaro PA. Hepatocyte growth factor is upregulated in ischemic retina and contributes to retinal vascular leakage and neovascularization. FASEB BioAdvances. 2020;2:219–233. https://doi.org/10.1096/fba.2019-00074